Can platinib be given at half dose? How long do the effects last?

The recommended dose of platinib is usually 400 mg once daily. This dosage is determined based on rigorous clinical research and practical experience to ensure the effectiveness and safety of the drug. Therefore, under routine circumstances, patients are not advised to take half-dose (ie 200mg). Taking half the dose may affect the therapeutic effect of the drug and prevent it from achieving the expected anti-tumor effect.

In some special circumstances, such as when patients experience drug intolerance or adverse reactions, doctors may consider adjusting the dosage. This adjustment is usually made under close physician supervision to ensure patient safety and therapeutic effectiveness. However, it should be noted that this dose adjustment is not equivalent to regular half-dose administration, but is a personalized adjustment based on the specific situation of the patient.

The duration of effect of Platinib varies among individuals and an exact time frame cannot be given. Its duration is affected by many factors, including the severity of the patient's condition, drug response, tolerance, and treatment regimen.

In clinical trials, platinib has shown significant efficacy against RET fusion-positive non-small cell lung cancer and other diseases. After using platinib, some patients' conditions were effectively controlled and their quality of life was significantly improved. However, as treatment progresses, some patients may develop drug resistance or disease progression, at which time the treatment regimen may need to be adjusted.

To maintain the therapeutic effects of Platinib, patients should be regularly evaluated and monitored by their physician. The doctor will promptly adjust the treatment plan according to the patient's specific situation to ensure that the drug can continue to work effectively.